Search
Faeth Therapeutics Ord Shs
FTHAdd to Watchlist
29.050USD
-2.500-7.92%
Close 09-23 16:00（ET）
748.91MMarket Cap
0.00P/E TTM
FTH Analyst Recommendation Trends
In the current month, FTH has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. FTH average Analyst price target in the last month is 56.667.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
4
4
1
0
0
0
1
1
4
3
0
0
0
0
0
0
0
0
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
7
2
1
1
1
2
2
Financial Forecasting
Based on analysts' estimates, FTH EPS is projected to reach -0.789 in FY2026Q3, following reported EPS of -2.837 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025
FY2026Q1
FY2026Q2
FY2025Q4
FY2026Q3
FY2026Q4
Forecast
--
-0.62
-3.05
-4.81
-0.79
-0.77
Actual
-16.72
-131.45
-2.84
--
--
--
Surprise
--
-21101.79%
+6.94%
--
--
--
FAQs
How have Faeth Therapeutics Ord ShsFTH's recent earnings per share performed?
The market expectation was USD -2.84, while Faeth Therapeutics Ord ShsFTH's earnings per share (EPS) for the previous quarter was USD -131.45. EPS for the next quarter is expected at USD -0.79.
What is the analyst rating for Faeth Therapeutics Ord Shs?
Based on the ratings of Faeth Therapeutics Ord Shs's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.